arrow
O

Oliver W. Press

Fred Hutchinson Cancer Center
H指数:84
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma

钇-90 Anti-CD45免疫治疗后自体造血干细胞移植治疗复发或难治性淋巴瘤

2021-01-017
OAAI
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA
2020-12-027
OAAI
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma
2020-04-229
OAAI
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia

钇90标记的anti-CD45抗体后进行低强度造血细胞移植治疗复发/难治性白血病或骨髓增生异常

2019-10-0316
OAAI
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
2019-08-1510
OAAI
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
2019-05-01195
OAAI
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL
2017-12-1162
OA
NCCN Guidelines® Insights Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017 Featured Updates to the NCCN Guidelines
2017-03-0848
OAAI
Non-Hodgkin's Lymphomas, Version 3.2016 Featured Updates to the NCCN Guidelines
2016-09-01106
OAAI
Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208
2016-07-124
OAAI
Diffuse Large B-Cell Lymphoma Version 1.2016 Clinical Practice Guidelines in Oncology
2016-02-0583
OAAI